IRVINE, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), a leading developer of surgical products used in the treatment of patients suffering from severe angina, today reported financial results for its third quarter ended September 30, 2008.
Third Quarter Financial Results
Sales in the third quarter of 2008 totaled $2,618,000, a 25% decrease from the prior year third quarter sales of $3,486,000. The lower revenue in the current year quarter is primarily attributable to a $534,000, or 59%, decrease in capital sales, and a $326,000, or 14%, decrease in disposable handpiece revenue as compared with the prior year quarter.
Sales in the first nine months of 2008 totaled $9,719,000, an increase of approximately $427,000 or 5% from sales of $9,292,000 in the first nine months of 2007. The year to date increase as compared with the prior year period is primarily attributable to a $712,000, or 38%, increase in capital sales offset by a $255,000, or 4%, decrease in disposable handpiece revenue.
The Company reported a third quarter 2008 operating loss of $310,000 as compared with an operating income of $679,000 in the prior year quarter. The Company's net loss for the quarter was $308,000, or $0.01 per diluted share, as compared with a net income of $590,000, or $0.01 per diluted share, in the 2007 third quarter.
For the first nine months of 2008, Cardiogenesis reported operating income of $235,000 as compared with $888,000 for the same period in the prior year. Net income for the first nine months of 2008 was $258,000, or $0.01 per diluted share, compared with $662,000, or $0.01 per diluted share, for the first nine months of 2007.
Gross profit decreased by $603,000 to $2,144,000 in the current year
quarter as compared with $2,747,000 for the 2007 third quarter. Gross
margin was 82% of net revenues for the quarter ended September 30, 2008 as
compared with a 79% gross margin in the third
|SOURCE Cardiogenesis Corporation|
Copyright©2008 PR Newswire.
All rights reserved